FDA approves novel topical retinoid trifarotene for acne. (cover story)

DRUG side effects; ACNE; CELL receptors; CLINICAL competence; DERMATOLOGISTS; RETINOIDS; CUTANEOUS therapeutics; UNITED States. Food & Drug Administration; TREATMENT effectiveness

The article announces the approval by the U.S. Food and Drug Administration (FDA) of the novel topical retinoid trifarotene marketed as Aklief Cream by Galderma, for the treatment of acne vulgaris. Topics covered include the findings of the clinical trials to study the drug's safety and efficacy, adverse reactions to trifarotene, and the lack of studies to establish its safety and effectiveness in pediatric populations.